1. Home
  2. NAMS vs BLKB Comparison

NAMS vs BLKB Comparison

Compare NAMS & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • BLKB
  • Stock Information
  • Founded
  • NAMS 2019
  • BLKB 1981
  • Country
  • NAMS Netherlands
  • BLKB United States
  • Employees
  • NAMS N/A
  • BLKB N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • BLKB Computer Software: Prepackaged Software
  • Sector
  • NAMS Health Care
  • BLKB Technology
  • Exchange
  • NAMS Nasdaq
  • BLKB Nasdaq
  • Market Cap
  • NAMS 3.1B
  • BLKB 2.7B
  • IPO Year
  • NAMS N/A
  • BLKB 2004
  • Fundamental
  • Price
  • NAMS $40.29
  • BLKB $56.34
  • Analyst Decision
  • NAMS Strong Buy
  • BLKB Hold
  • Analyst Count
  • NAMS 10
  • BLKB 2
  • Target Price
  • NAMS $44.80
  • BLKB $70.50
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • BLKB 402.6K
  • Earning Date
  • NAMS 11-05-2025
  • BLKB 10-29-2025
  • Dividend Yield
  • NAMS N/A
  • BLKB N/A
  • EPS Growth
  • NAMS N/A
  • BLKB N/A
  • EPS
  • NAMS N/A
  • BLKB N/A
  • Revenue
  • NAMS $35,243,000.00
  • BLKB $1,136,093,000.00
  • Revenue This Year
  • NAMS N/A
  • BLKB N/A
  • Revenue Next Year
  • NAMS N/A
  • BLKB $4.09
  • P/E Ratio
  • NAMS N/A
  • BLKB N/A
  • Revenue Growth
  • NAMS 4.91
  • BLKB N/A
  • 52 Week Low
  • NAMS $14.06
  • BLKB $54.56
  • 52 Week High
  • NAMS $41.47
  • BLKB $88.95
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 61.84
  • BLKB 38.20
  • Support Level
  • NAMS $36.59
  • BLKB $54.56
  • Resistance Level
  • NAMS $40.88
  • BLKB $58.00
  • Average True Range (ATR)
  • NAMS 2.59
  • BLKB 1.97
  • MACD
  • NAMS -0.09
  • BLKB -0.31
  • Stochastic Oscillator
  • NAMS 90.44
  • BLKB 26.85

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

Share on Social Networks: